The main goal of treating rheumatic diseases is to achieve rapid and effective suppression of inflammation. More and more drugs have been proven to be able to achieve these goals nowadays. The current practice is to give a recommended dose of drugs to our patients according to the body weight, risk factors and tolerance, etc. However, all our patients are different individuals who have different pharmacokinetics, and this difference in pharmacokinetics can affect the true drug concentration that is working inside them. This may create
. VOIOSU T, BENGUŞ A, BĂLĂNESCU P, DINU R, VOIOSU A, BĂICUŞ C et al. Rapid fecal calprotectin testing predicts mucosal healing better than C-reactive protein and Serum tumor necrosis factor α in patients with ulcerative colitis. Rom J Intern Med. 2015; 53(3):253-60.
18. DOTAN I, RON Y, YANAI H, BECKER S, FISHMAN S, YAHAV L et al. Patient factors that increase infliximab clearance and shorten half-life in inflammatory bowel disease: a population pharmacokinetic study. Inflamm Bowel Dis. 2014; 20(12):2247-59.
19. BRANDSE JF, MATHÔT RA, VAN
., AKITA W., KUYAMA T., TAKADA S., ASAI T., et al. Diagnostic usefulness of bone mineral density and biochemical markers of bone turnover in predicting fracture in CKD stage 5D patients – a single-center cohort study. Nephrol Dial Transplant 2012; 27 :345-51.
27. LIN JH. Bisphosponates: a review of their pharmacokinetic properties . Bone. 1996; 18 (2):75-85.
28. CONTR P., GUARNERI V. Safety of intravenous and oral bisphosphonates and compliance with dosing regimen. The Oncologist.2004; 9 (Suppl 4): 28-37.
29. SHERRARD DJ., HERCZ G., PEI Y